Crizotinib and erlotinib (an EGFR inhibitor) showed synergistic effects in orthotopic tumor model mice [97], and it is tempting to propose the combination of Crizotinib and erlotinib in patients with HGFR+/EGFR+ GBM. The gene discussed is EGFR; the disease is neoplasm.